Let’s look at the key reasons that are pushing Ultragenyx Pharmaceutical Inc (RARE) to new highs

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) on Friday, soared 0.85% from the previous trading day, before settling in for the closing price of $41.15. Within the past 52 weeks, RARE’s price has moved between $37.02 and $60.37.

During the last 5-year period, the sales growth of Healthcare Sector giant was 53.47%. The company achieved an average annual earnings per share of 23.78%. With a float of $83.36 million, this company’s outstanding shares have now reached $92.24 million.

Let’s determine the extent of company efficiency that accounts for 1276 employees. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.

Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ultragenyx Pharmaceutical Inc is 9.74%, while institutional ownership is 92.11%. The most recent insider transaction that took place on Dec 30 ’24, was worth 495,231. In this transaction President & CEO of this company sold 11,727 shares at a rate of $42.23, taking the stock ownership to the 2,183,985 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Officer proposed sale 11,727 for $42.23, making the entire transaction worth $495,264.

Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 23.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators

Ultragenyx Pharmaceutical Inc (RARE) is currently performing well based on its current performance indicators. A quick ratio of 2.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.39.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.46, a number that is poised to hit -1.37 in the next quarter and is forecasted to reach -5.14 in one year’s time.

Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)

Looking closely at Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days average volume was 1.05 million, which is a drop from its year-to-date volume of 1.51 million. As of the previous 9 days, the stock’s Stochastic %D was 26.54%. Additionally, its Average True Range was 1.67.

During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 7.14%, which indicates a significant decrease from 20.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.12% in the past 14 days, which was lower than the 31.86% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $47.54, while its 200-day Moving Average is $47.66. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $41.94. Second resistance stands at $42.37. The third major resistance level sits at $42.79. If the price goes on to break the first support level at $41.08, it is likely to go to the next support level at $40.66. Now, if the price goes above the second support level, the third support stands at $40.23.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats

Market capitalization of the company is 3.86 billion based on 92,344K outstanding shares. Right now, sales total 434,250 K and income totals -606,640 K. The company made 139,490 K in profit during its latest quarter, and -133,520 K in sales during its previous quarter.